Investor Presentation: First Nine Months of 2020
57
Investor presentation
First nine months of 2020
The AM833 phase 2 monotherapy trial and phase 1 combination
with semaglutide trial decreased weight by 10.8% and 17.1%
Weight loss for AM833 plus lifestyle intervention¹
Weight loss for AM833 and semaglutide in phase 12
% change in
body weight
0
-4
-8
% change in
body weight
Mean baseline: 107.4 kg
-4
-8
-12
Mean baseline: 95.1 kg
Novo Nordisk®
- 9.5%
-12
0
Weeks
AM833
0.3mg
Placebo
AM833
0.6mg
Lira
AM833
1.2mg
AM833
2.4mg
AM833
4.5mg
3.0mg
26
-16
10.8%
-20
0
AM833 0.3 mg
sema 2.4 mg
sema 2.4 mg
AM833 0.16 mg
sema 2.4 mg
Weeks
AM833 0.6 mg
sema 2.4 mg
AM833 1.2 mg
sema 2.4 mg
17.1%
20
AM833 2.4 mg
sema 2.4 mg
1 Lifestyle intervention is defined as counselling for a reduced-calorie diet and increased physical activity. Data is based on the trial product estimand: treatment effect if all people adhered to treatment and did not initiate other anti-obesity therapies
2 Data are observed means, 20 week phase 1b trial dosing increments with semaglutide and AM833 once-weekly with a 16 week dose-escalation regimen. Data is based on the trial product estimand.View entire presentation